ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
63 announcements
Aurobindo Pharma's subsidiary, CuraTeQ Biologics, announced positive Phase 3 results for its Omalizumab biosimilar (BP11). The study met all primary endpoints for efficacy and safety, showing equivalence to Xolair. The company plans to file for EMA and FDA regulatory approvals by the end of Q2 2026.
Aurobindo Pharma approved the slump sale of its domestic branded generic formulations business to its subsidiary, Auropharm Limited, for ₹143.21 Crore. The transaction aims to streamline operations and accelerate domestic growth. Completion is expected within 120 days, with economic benefits effective from April 1, 2026.
Aurobindo Pharma's Board approved a ₹800 Crore share buyback at ₹1,475 per share via the tender offer route. The buyback represents 0.93% of paid-up equity capital. The record date is set for April 17, 2026, to determine eligibility for shareholders, including promoters.